This is only the cover of the book. Download the whole Toolkit at: www.cdc.gov/reproductivehealth/Refugee/
Understanding the reproductive health needs of conflict-affected women will enable organizations to implement and enhance programs and services to improve the health of women and their fam...ilies. The Reproductive Health Assessment Toolkit (RHA) for Conflict-Affected Women provides user-friendly tools to quantitatively assess the reproductive health needs of conflict-affected women aged 15–49 years. The RHA Toolkit enables field staff to collect data to inform program planning, monitoring, evaluation, and advocacy. It promotes using the collected data to enhance services and improve the reproductive health of women and their families.
more
Esta guía trata de la primera ayuda psicológica, un modo práctico y humano para ayudar y apoyar a nuestros semejantes en graves situaciones de crisis. Se ha pensado para personas que se tienen la posibilidad de ayudar a
otras que han experimentado un hecho extremadamente angustiante. Proporciona... un marco de
trabajo para apoyar a las personas respetando su dignidad, cultura y capacidades. A pesar de su
nombre, la primera ayuda psicológica se ocupa tanto del apoyo social como del psicológico.
more
Interim Recommendation published 19 September 2014. These recommendations reflect current understanding of Ebola virus disease (EVD) and are intended for national laboratory staff performing diagnostic testing to detect Ebola virus.
CAFOD Policy Briefing Paper
Report of Meeting: 4 November 2014, Roma
Plos Current Outbreaks November 21, 2014
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more